Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial - PubMed (original) (raw)
Randomized Controlled Trial
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial
Julio Sotelo et al. Ann Intern Med. 2006.
Abstract
Background: Malignant cell clones resistant to chemotherapy and radiotherapy frequently lead to treatment failure in patients with glioblastoma multiforme. Preliminary studies suggest that adding chloroquine to conventional therapy may improve treatment outcomes.
Objective: To examine the effect of adding chloroquine to conventional therapy for glioblastoma multiforme.
Design: Randomized, double-blind, placebo-controlled trial.
Setting: National Institute of Neurology and Neurosurgery of Mexico.
Patients: 30 patients with surgically confirmed glioblastoma confined to 1 cerebral hemisphere, with a Karnofsky performance score greater than 70, no comorbid disease, and age younger than 60 years.
Interventions: Oral chloroquine at 150 mg/d for 12 months beginning on postoperative day 5 or placebo. All patients received conventional chemotherapy and radiotherapy.
Measurements: Primary outcome was survival after surgery; surviving patients were followed up to October 2005. Periodic evaluation using the Karnofsky scale and imaging studies, as well as hematologic tests and ophthalmologic examinations, was done in all patients.
Results: Median survival after surgery was 24 months for chloroquine-treated patients and 11 months for controls. At the end of the observation period, 6 patients treated with chloroquine had survived 59, 45, 30, 27, 27, and 20 months, respectively; 3 patients from the control group had survived 32, 25, and 22 months, respectively. Although not statistically significantly different, the rate of death with time was approximately half as large in patients receiving chloroquine as in patients receiving placebo (hazard ratio, 0.52 [95% CI, 0.21 to 1.26]; P = 0.139).
Limitations: The observed advantage of chloroquine may be due to chance; differences in pretreatment characteristics and conventional treatment regimens could not be adjusted for because of the small sample size.
Conclusions: Chloroquine may improve mid-term survival when given in addition to conventional therapy for glioblastoma multiforme. These results suggest that larger, more definitive studies of chloroquine as adjuvant therapy for glioblastoma are warranted.
Trial registration: ClinicalTrials.gov NCT00224978.
Comment in
- New treatments for malignant gliomas: careful evaluation and cautious optimism required.
Gilbert MR. Gilbert MR. Ann Intern Med. 2006 Mar 7;144(5):371-3. doi: 10.7326/0003-4819-144-5-200603070-00015. Ann Intern Med. 2006. PMID: 16520480 No abstract available.
Summary for patients in
- Summaries for patients. Adding chloroquine to conventional chemotherapy and radiotherapy for glioblastoma multiforme.
[No authors listed] [No authors listed] Ann Intern Med. 2006 Mar 7;144(5):I31. doi: 10.7326/0003-4819-144-5-200603070-00004. Ann Intern Med. 2006. PMID: 16520470 No abstract available.
Similar articles
- Summaries for patients. Adding chloroquine to conventional chemotherapy and radiotherapy for glioblastoma multiforme.
[No authors listed] [No authors listed] Ann Intern Med. 2006 Mar 7;144(5):I31. doi: 10.7326/0003-4819-144-5-200603070-00004. Ann Intern Med. 2006. PMID: 16520470 No abstract available. - Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine.
Briceño E, Reyes S, Sotelo J. Briceño E, et al. Neurosurg Focus. 2003 Feb 15;14(2):e3. doi: 10.3171/foc.2003.14.2.4. Neurosurg Focus. 2003. PMID: 15727424 Clinical Trial. - Therapy of glioblastoma multiforme: a cumulative experience of 10 years.
Obwegeser A, Ortler M, Seiwald M, Ulmer H, Kostron H. Obwegeser A, et al. Acta Neurochir (Wien). 1995;137(1-2):29-33. doi: 10.1007/BF02188776. Acta Neurochir (Wien). 1995. PMID: 8748864 - The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review.
Dixit S, Hingorani M, Achawal S, Scott I. Dixit S, et al. Br J Neurosurg. 2011 Aug;25(4):459-69. doi: 10.3109/02688697.2010.550342. Epub 2011 Feb 23. Br J Neurosurg. 2011. PMID: 21344976 Review. - Current developments in the radiotherapy approach to elderly and frail patients with glioblastoma multiforme.
Roa W, Xing JZ, Small C, Kortmann R, Miriamanoff R, Okunieff P, Shibamoto Y, Jeremic B. Roa W, et al. Expert Rev Anticancer Ther. 2009 Nov;9(11):1643-50. doi: 10.1586/era.09.128. Expert Rev Anticancer Ther. 2009. PMID: 19895247 Review.
Cited by
- Cellular and molecular events in colorectal cancer: biological mechanisms, cell death pathways, drug resistance and signalling network interactions.
Yan L, Shi J, Zhu J. Yan L, et al. Discov Oncol. 2024 Jul 20;15(1):294. doi: 10.1007/s12672-024-01163-1. Discov Oncol. 2024. PMID: 39031216 Free PMC article. Review. - Malignancy in systemic lupus erythematosus: relation to disease characteristics in 92 patients - a single center retrospective study.
Kosałka-Węgiel J, Pacholczak-Madej R, Dziedzic R, Siwiec-Koźlik A, Spałkowska M, Milewski M, Zaręba L, Bazan-Socha S, Korkosz M. Kosałka-Węgiel J, et al. Rheumatol Int. 2024 Sep;44(9):1701-1713. doi: 10.1007/s00296-024-05623-3. Epub 2024 Jun 8. Rheumatol Int. 2024. PMID: 38850326 Free PMC article. - Guidelines for the role of autophagy in drug delivery vectors uptake pathways.
Dowaidar M. Dowaidar M. Heliyon. 2024 Apr 24;10(9):e30238. doi: 10.1016/j.heliyon.2024.e30238. eCollection 2024 May 15. Heliyon. 2024. PMID: 38707383 Free PMC article. Review. - Crosstalk between cancer-associated fibroblasts and regulated cell death in tumors: insights into apoptosis, autophagy, ferroptosis, and pyroptosis.
Chen C, Liu J, Lin X, Xiang A, Ye Q, Guo J, Rui T, Xu J, Hu S. Chen C, et al. Cell Death Discov. 2024 Apr 22;10(1):189. doi: 10.1038/s41420-024-01958-9. Cell Death Discov. 2024. PMID: 38649701 Free PMC article. Review. - Tumor-associated macrophages affect the treatment of lung cancer.
Yu Z, Zou J, Xu F. Yu Z, et al. Heliyon. 2024 Apr 6;10(7):e29332. doi: 10.1016/j.heliyon.2024.e29332. eCollection 2024 Apr 15. Heliyon. 2024. PMID: 38623256 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical